Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma, Aspirin-Induced | 1 | 2021 | 7 | 0.750 |
Why?
|
| Head Injuries, Penetrating | 1 | 2020 | 6 | 0.700 |
Why?
|
| Cerebrovascular Trauma | 1 | 2020 | 6 | 0.700 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2020 | 3 | 0.700 |
Why?
|
| Aspirin | 2 | 2021 | 222 | 0.700 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2020 | 74 | 0.660 |
Why?
|
| Agammaglobulinemia | 1 | 2018 | 39 | 0.630 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 303 | 0.630 |
Why?
|
| Aneurysm, False | 1 | 2020 | 101 | 0.620 |
Why?
|
| Immunity, Humoral | 1 | 2018 | 68 | 0.610 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 501 | 0.590 |
Why?
|
| Hydrocephalus | 1 | 2020 | 236 | 0.580 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 225 | 0.570 |
Why?
|
| Neurosurgical Procedures | 1 | 2020 | 296 | 0.570 |
Why?
|
| Community-Acquired Infections | 1 | 2018 | 240 | 0.540 |
Why?
|
| Peanut Hypersensitivity | 3 | 2024 | 71 | 0.540 |
Why?
|
| Pneumonia | 1 | 2018 | 325 | 0.490 |
Why?
|
| Mass Screening | 1 | 2018 | 778 | 0.420 |
Why?
|
| Desensitization, Immunologic | 3 | 2024 | 95 | 0.410 |
Why?
|
| Arachis | 2 | 2024 | 70 | 0.400 |
Why?
|
| Hypersensitivity | 2 | 2021 | 178 | 0.310 |
Why?
|
| Immunoglobulin G | 2 | 2021 | 758 | 0.280 |
Why?
|
| Telemedicine | 3 | 2021 | 422 | 0.270 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 360 | 0.240 |
Why?
|
| Allergens | 3 | 2024 | 244 | 0.240 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 378 | 0.240 |
Why?
|
| Infusions, Subcutaneous | 2 | 2021 | 7 | 0.230 |
Why?
|
| Pneumococcal Vaccines | 2 | 2021 | 168 | 0.200 |
Why?
|
| Nasal Polyps | 1 | 2020 | 24 | 0.180 |
Why?
|
| Remote Consultation | 1 | 2020 | 22 | 0.180 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 49 | 0.180 |
Why?
|
| Immune Tolerance | 1 | 2021 | 145 | 0.180 |
Why?
|
| Allergy and Immunology | 1 | 2020 | 24 | 0.170 |
Why?
|
| Diphenhydramine | 1 | 2020 | 10 | 0.170 |
Why?
|
| Rhinitis | 1 | 2020 | 38 | 0.170 |
Why?
|
| Occupational Injuries | 1 | 2020 | 10 | 0.170 |
Why?
|
| Nut Hypersensitivity | 1 | 2019 | 7 | 0.170 |
Why?
|
| Ventriculostomy | 1 | 2020 | 35 | 0.170 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 473 | 0.170 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 184 | 0.170 |
Why?
|
| Nuts | 1 | 2019 | 15 | 0.170 |
Why?
|
| Central Nervous System Cysts | 1 | 2019 | 11 | 0.170 |
Why?
|
| Cerebral Angiography | 1 | 2020 | 102 | 0.170 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2021 | 201 | 0.170 |
Why?
|
| Epidermal Cyst | 1 | 2019 | 19 | 0.170 |
Why?
|
| Craniopharyngioma | 1 | 2019 | 33 | 0.160 |
Why?
|
| Craniotomy | 1 | 2020 | 108 | 0.160 |
Why?
|
| Rituximab | 1 | 2020 | 157 | 0.160 |
Why?
|
| Drug Hypersensitivity | 1 | 2020 | 96 | 0.160 |
Why?
|
| Dermoid Cyst | 1 | 2019 | 35 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 103 | 0.160 |
Why?
|
| Epinephrine | 1 | 2020 | 175 | 0.160 |
Why?
|
| Anaphylaxis | 1 | 2020 | 77 | 0.160 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 162 | 0.160 |
Why?
|
| Pituitary Neoplasms | 1 | 2019 | 82 | 0.160 |
Why?
|
| Pandemics | 3 | 2021 | 1102 | 0.150 |
Why?
|
| Drainage | 1 | 2020 | 254 | 0.150 |
Why?
|
| Male | 10 | 2024 | 59515 | 0.140 |
Why?
|
| Humans | 15 | 2024 | 122287 | 0.120 |
Why?
|
| Adult | 5 | 2021 | 28728 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2021 | 5962 | 0.120 |
Why?
|
| Length of Stay | 1 | 2018 | 1271 | 0.110 |
Why?
|
| Female | 9 | 2024 | 64880 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2030 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2024 | 668 | 0.090 |
Why?
|
| Telephone | 2 | 2021 | 109 | 0.090 |
Why?
|
| Aged | 4 | 2021 | 18783 | 0.080 |
Why?
|
| Time Factors | 1 | 2020 | 6181 | 0.080 |
Why?
|
| Betacoronavirus | 2 | 2020 | 289 | 0.070 |
Why?
|
| Risk Factors | 1 | 2018 | 9901 | 0.060 |
Why?
|
| Middle Aged | 5 | 2021 | 25636 | 0.060 |
Why?
|
| Diphtheria Toxoid | 1 | 2021 | 7 | 0.050 |
Why?
|
| Diphtheria | 1 | 2021 | 15 | 0.050 |
Why?
|
| Tetanus Toxoid | 1 | 2021 | 45 | 0.050 |
Why?
|
| Tetanus | 1 | 2021 | 21 | 0.050 |
Why?
|
| Serogroup | 1 | 2021 | 49 | 0.050 |
Why?
|
| Electronics | 1 | 2020 | 43 | 0.040 |
Why?
|
| Mouthwashes | 1 | 2020 | 10 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 729 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 37 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2020 | 126 | 0.040 |
Why?
|
| Office Visits | 1 | 2020 | 75 | 0.040 |
Why?
|
| Skin Tests | 1 | 2019 | 75 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 300 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2021 | 371 | 0.040 |
Why?
|
| Immunoglobulin E | 1 | 2019 | 152 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 540 | 0.040 |
Why?
|
| Outpatients | 1 | 2020 | 252 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 267 | 0.040 |
Why?
|
| Adenoma | 1 | 2019 | 134 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2022 | 658 | 0.030 |
Why?
|
| Infant | 2 | 2024 | 12301 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2020 | 525 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1238 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2024 | 13775 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 511 | 0.030 |
Why?
|
| Inpatients | 1 | 2020 | 487 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1166 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 8759 | 0.030 |
Why?
|
| Child | 3 | 2020 | 24058 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1490 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2777 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 691 | 0.030 |
Why?
|
| Adolescent | 2 | 2020 | 18934 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3301 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1913 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 6289 | 0.020 |
Why?
|